Literature DB >> 15516607

Myocardial infarction: optimization of inversion times at delayed contrast-enhanced MR imaging.

Ankur Gupta1, Vivian S Lee, Yiu-Cho Chung, James S Babb, Orlando P Simonetti.   

Abstract

Seventeen patients underwent magnetic resonance (MR) imaging for myocardial viability with a protocol approved by the institutional review board and gave written informed consent. Breath-hold cine inversion-recovery segmented k-space true fast imaging with steady-state precession sequence, referred to as inversion time (TI) mapping, was performed to determine optimal TI for myocardial infarction inversion-recovery imaging. From TI mapping, optimal TI was 180-315 msec 10-15 minutes after administration of 0.15 mmol/kg of gadolinium-based contrast material. At that optimal TI, relative signal intensity of infarcted myocardium compared with uninfarcted myocardium was maximal (mean +/- standard deviation, 297.8% +/- 86.5), whereas signal-to-noise ratio of uninfarcted myocardium was minimal (4.5 +/- 1.2). When applied to conventional myocardial infarction inversion-recovery imaging, optimal TI resulted in nulling of signal intensity of uninfarcted myocardium in all patients and in excellent conspicuity of infarcted myocardium in all nine patients with visible infarction. (c) RSNA, 2004

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15516607     DOI: 10.1148/radiol.2333032004

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  23 in total

1.  Optimization of myocardial nulling in pediatric cardiac MRI.

Authors:  Edythe B Tham; Ryan W Hung; Kimberley A Myers; Cinzia Crawley; Michelle L Noga
Journal:  Pediatr Radiol       Date:  2011-10-18

2.  Quantitative myocardial distribution volume from dynamic contrast-enhanced MRI.

Authors:  Nathan A Pack; Edward V R Dibella; Brent D Wilson; Christopher J McGann
Journal:  Magn Reson Imaging       Date:  2008-02-20       Impact factor: 2.546

3.  Cardiac magnetic resonance imaging in small rodents using clinical 1.5 T and 3.0 T scanners.

Authors:  Wesley D Gilson; Dara L Kraitchman
Journal:  Methods       Date:  2007-09       Impact factor: 3.608

Review 4.  Updates on Stress Imaging Testing and Myocardial Viability With Advanced Imaging Modalities.

Authors:  Sandeep S Hedgire; Michael Osborne; Daniel J Verdini; Brian B Ghoshhajra
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-04

5.  [Late gadolinium enhancement in the diagnostics of ischemic heart disease: technical principles, contrast optimization and clinical application].

Authors:  K U Bauner; A Biffar; M Greif; A Becker; M Picciolo; D Theisen; T A Sandner; M Notohamiprodjo; M F Reiser; B J Wintersperger
Journal:  Radiologe       Date:  2010-06       Impact factor: 0.635

6.  MRI demonstration of acute myocardial infarction due to posttraumatic coronary artery dissection.

Authors:  Savas M Tepe; James F Glockner; Paul Julsrud
Journal:  Int J Cardiovasc Imaging       Date:  2005-07-23       Impact factor: 2.357

7.  Volumetric late gadolinium-enhanced myocardial imaging with retrospective inversion time selection.

Authors:  Steve Kecskemeti; Kevin Johnson; Christopher J François; Mark L Schiebler; Orhan Unal
Journal:  J Magn Reson Imaging       Date:  2013-02-06       Impact factor: 4.813

Review 8.  Cardiac imaging techniques for physicians: late enhancement.

Authors:  Peter Kellman; Andrew E Arai
Journal:  J Magn Reson Imaging       Date:  2012-09       Impact factor: 4.813

9.  Rapid T1 quantification based on 3D phase sensitive inversion recovery.

Authors:  Marcel J B Warntjes; Johan Kihlberg; Jan Engvall
Journal:  BMC Med Imaging       Date:  2010-08-17       Impact factor: 1.930

10.  Late gadolinium enhancement magnetic resonance imaging for the assessment of myocardial infarction: comparison of image quality between single and double doses of contrast agents.

Authors:  Yeo Koon Kim; Eun-Ah Park; Whal Lee; Sang Yoon Kim; Jin Wook Chung
Journal:  Int J Cardiovasc Imaging       Date:  2014-08-03       Impact factor: 2.357

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.